Skip to main content

Obeticholic acid Disease Interactions

There are 3 disease interactions with obeticholic acid.

Major

Obeticholic acid (applies to obeticholic acid) biliary obstruction

Major Potential Hazard, Moderate plausibility.

Obeticholic acid is contraindicated in patients with complete biliary obstruction.

References

  1. (2016) "Product Information. Ocaliva (obeticholic acid)." Intercept Pharmaceuticals, Inc.
Major

Obeticholic acid (applies to obeticholic acid) liver impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with primary biliary cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when obeticholic acid was dosed more frequently than recommended. The recommended starting dosage is 5 mg once weekly for patients with Child-Pugh Class B or C hepatic impairment or a prior hepatic decompensation event. Patients in treatment should be closely monitored for progression of PBC disease, including liver- related complications, with laboratory and clinical assessments. Dosage adjustment, interruption or discontinuation may be required.

References

  1. (2016) "Product Information. Ocaliva (obeticholic acid)." Intercept Pharmaceuticals, Inc.
Moderate

Obeticholic acid (applies to obeticholic acid) lipids disorder

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hyperlipidemia

Patients with primary biliary cholangitis generally exhibit hyperlipidemia characterized by a significant elevation in total cholesterol primarily due to increased levels of high-density lipoprotein-cholesterol (HDL-C). Exercise care when using obeticholic acid in patients with lipids disorder. It is recommended to monitor patients for changes in serum lipid levels during treatment with obeticholic acid. For patients who do not respond to treatment after 1 year at the highest recommended dosage that can be tolerated (maximum of 10 mg once daily), and who experience a reduction in HDL-C, weigh the potential risks against the benefits of continuing treatment.

References

  1. (2016) "Product Information. Ocaliva (obeticholic acid)." Intercept Pharmaceuticals, Inc.

Obeticholic acid drug interactions

There are 62 drug interactions with obeticholic acid.

Obeticholic acid alcohol/food interactions

There are 2 alcohol/food interactions with obeticholic acid.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer